Skip to main content
SciBX: Science-Business eXchange
As published Thursday, November 20, 2014


  • Cover Story: Tapping TOPK

    By Benjamin Boettner, Senior Writer

    Although targeting proteins involved in cell division is falling out of fashion in cancer research because of the difficulty of distinguishing between diseased and normal cells, several companies are still exploring enzymes that could be tractable targets. A new inhibitor of TOPK-an enzyme involved in mitosis-could provide an option for cancers unserved by targeted therapies, based on findings in mice that liposomal delivery reduces the compound's toxicity, keeps it away from hematopoietic cells and increases its therapeutic index.1

    The inhibitor was developed by Japanese biotech OncoTherapy Science Inc. in collaboration with researchers at The University of Chicago. The team is optimizing the formulation for use in solid tumors but is starting with a Phase I trial in acute myelogenous leukemia (AML), in which the potential for hematopoietic toxicity would not pose a significant risk.

    Full Article

Distillery

  • This Week in Therapeutics

    Overcoming oncogenic KRAS-driven chemotherapy resistance by blocking NRF2 signaling; trifunctional arylpiperazine analogs as antipsychotic agents; inhibiting TRPM2 or RAC1 to treat ischemic kidney injury; and more...

  • more therapeutics news
  • This Week in Techniques

    Lysyl oxidase to enhance tensile properties of musculoskeletal grafts; a sorbitol-based PET imaging agent to help diagnose and monitor Enterobacteriaceae infections; genetic variants near estrogen receptor-alpha to predict the risk of breast cancer in Latina women; and more...

  • more techniques news
Subscribe Now
Free Trial